Drugs / TRK-700
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03043248 | Feb → May 2017 | — | Toray Industries, Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02701374 | Mar 2016 → Jul 2017 | postherpetic neuralgia | Toray Industries, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRK-700 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03043248 ↗ |
| Route | Oral | “repeated oral doses of TRK-700” NCT02701374 ↗ |